RWJ 67657 is an orally active inhibitor of the MAP kinases p38alpha and p38beta (IC50s = 1 and 11 uM, respectively, in vitro) that is inactive against p38gamma and p38delta, as well as several other kinases. It blocks the release of TNF-alpha and IL-1beta from peripheral blood mononuclear cells stimulated with LPS (IC50s = 3 and 11 nM, respectively) and inhibits TNF-alpha production in LPS-treated mice and rats. RWJ 67657 potently blocks the proliferation of CD4+ peripheral blood T cells induced by CD28 stimulation alone (IC50 = 0.5-4nM). It is commonly used to study the roles of p38alpha and p38beta in cellular and whole animal systems. Alternate Names: 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol, 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-phenylpropyl)-5-(4-Pyridyl)imidazole, JNJ 3026582, RWJ 67657 CAS Number: 215303-72-3 Formula: C27H24FN3O Molecular Weight: ~425.5 lambdamax: 241, 269 nm Purity: 95% Appearance: Supplied as a crystalline solid. Solubility: ~0.2mg/ml in a 1:4 solution of EtOH:PBS (pH 7.2), ~10mg/ml in EtOH, ~5mg/ml in DMSO, ~2mg/ml in DMF Storage and Stability: Store at 4C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Molekulargewicht:
425.5
Reinheit:
Highly Purified (~95%)
Formulierung:
Supplied as a crystalline solid.
CAS Nummer:
[215303-72-3]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
